- Distribution agreement covers more than 30 Intermediates
- Important step to optimize Brenntag’s portfolio for API synthesis
Brenntag, the global market leader in chemicals and ingredients distribution, today announced a new strategic partnership with Seqens for the distribution of non-GMP intermediates in Europe.
High-quality products are a cornerstone of the pharmaceutical industry. At every stage of chemical synthesis—whether introducing a functional group, performing a coupling reaction, or modifying a molecular structure—the need for perfectly aligned intermediates, both in terms of quality and documentation, remains absolutely critical.
This sole distribution agreement allows Brenntag to provide these high-quality intermediates from a well-known Global CDMO and ingredient manufacturer to a broad customer base, helping to optimize their way of synthesis. Seqens offers a reliable and competitive solution for customers’ non-GMP intermediate needs, while optimizing lead times and flexibility.
Brenntag customers can benefit from regulatory depth, quality, flexibility, global reliability, and a secure supply chain with production in Europe. This partnership will deliver improved availability of non-GMP pharmaceutical intermediates and expanded coverage in Europe through Brenntag’s logistics and commercial expertise.
Joakim Rehné, Regional President Brenntag Pharma EMEA says: “Our partnership with Seqens for intermediates marks a milestone in Brenntag’s commitment to the Pharma industry. By expanding our portfolio with these high-quality intermediates, we support our customers in all steps of their research phase. Gaining the Seqens expertise and strong team in our network of partners is a wonderful addition and we look forward to driving growth and future projects together.”
Alexandra Ngawa Zenang, Business Line Manager Pharma at Sequens, adds: “This partnership is part of our strategy to stay close to our customers and reinforce our presence in the European market. It enables us to respond quickly to market demands while maintaining our high standards of quality and safety.”
About Seqens:
Sequens is a global partner in health, personal care and specialty ingredients. We empower innovation to bring the best solutions to our customers, with a constant concern for sustainability. Relying on the skills of 3300 employees, we leverage a worldwide manufacturing network of 15 manufacturing sites and 9 state-of-the-art R&D centers in 9 countries. As an end-to-end player across the value chain, SEQENS offers a broad range of active ingredients, pharmaceutical intermediates, personal care & specialty ingredients. We innovate, develop and industrialize the most demanding molecules, and implement the best available technologies. Learn more at www.seqens.com
